2011-11-06 16:00:58 - New Pharmaceuticals market report from Global Markets Direct: "Neutropenia - Pipeline Review, H2 2011"

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2011', provides an overview of the Neutropenia therapeutic pipeline. This report provides information on the therapeutic development for Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neutropenia. 'Neutropenia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/267823_neutropenia_pipeline_review_h2_2011.a ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of

data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Neutropenia.
* A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Neutropenia pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Neutropenia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Neutropenia therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neutropenia Overview
Therapeutics Development
An Overview of Pipeline Products for Neutropenia
Neutropenia Therapeutics under Development by Companies
Neutropenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Neutropenia Therapeutics - Products under Development by Companies
Neutropenia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Neutropenia Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
Merck & Co., Inc.
Gamida Cell Ltd.
Mochida Pharmaceutical Co., Ltd.
Dong-A Pharmaceutical Co., Ltd.
Hanmi Pharmaceutical Co Ltd
Maxygen, Inc.
Mitsubishi Chemical Holdings Corporation
Teva Pharmaceutical Industries Limited
IR Biosciences Holdings, Inc.
Lupin Limited
NexMed, Inc.
Telik, Inc.
Lipoxen PLC
Green Cross Corporation
LTT Bio-Pharma Co., Ltd.
Microbio Co., Ltd.
Cellerant Therapeutics, Inc.
BioGeneriX AG
Med Discovery SA
Synageva BioPharma Corp.
Genexine Co., Ltd.
Bolder Biotechnology, Inc.
Welichem Biotech Inc.
USV Limited.
PharmaEssentia Corporation
Eurofarma
Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-6302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAXY-G34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDPK67b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viprovex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sustained Release G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Telintra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P1130 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GlycoPEG-GCSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVI-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mechanism of Action
R&D Progress
Filgrastim + Docetaxel + Epirubicin Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Docetaxel + Epirubicin Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neutroval - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FK463 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Busulfan + Cyclosporine + Fludarabine Phosphate + Methotrexate + Methylprednisolone + Filgrastim + Bone Marrow Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=267823&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.